 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || leiolizumab (ALTB-268) / AltruBio
Enrollment open, Trial completion date, Trial primary completion date: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Feb 18, 2025
P2, N=30, Recruiting, Sponsor: AltruBio Inc.
Active, not recruiting --> Recruiting | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Apr 2025 --> Oct 2025
- | leiolizumab (ALTB-268) / AltruBio
Enrollment closed: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Dec 27, 2024
P2, N=30, Active, not recruiting, Sponsor: AltruBio Inc.
Active, not recruiting --> Recruiting | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Apr 2025 --> Oct 2025 Recruiting --> Active, not recruiting
- ||| leiolizumab (ALTB-268) / AltruBio
Enrollment change: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Apr 24, 2024
P2, N=30, Recruiting, Sponsor: AltruBio Inc.
Recruiting --> Active, not recruiting N=15 --> 30
- | leiolizumab (ALTB-268) / AltruBio
Trial primary completion date: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Feb 15, 2024
P2, N=15, Recruiting, Sponsor: AltruBio Inc.
N=15 --> 30 Trial primary completion date: Dec 2024 --> Apr 2025
- ||| leiolizumab (ALTB-268) / AltruBio
Trial completion: A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers (clinicaltrials.gov) - Feb 5, 2024
P1, N=56, Completed, Sponsor: AltruBio Inc.
Trial primary completion date: Dec 2024 --> Apr 2025 Recruiting --> Completed
- || leiolizumab (ALTB-268) / AltruBio
Enrollment open: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Dec 27, 2023
P2, N=15, Recruiting, Sponsor: AltruBio Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | leiolizumab (ALTB-268) / AltruBio
Trial completion date, Trial initiation date, Trial primary completion date: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Dec 5, 2023
P2, N=15, Not yet recruiting, Sponsor: AltruBio Inc.
Not yet recruiting --> Recruiting .
- leiolizumab (ALTB-268) / AltruBio
Phase classification: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Nov 13, 2023
P2, N=15, Recruiting, Sponsor: AltruBio Inc.
. Phase classification: P2a --> P2
- || leiolizumab (ALTB-268) / AltruBio
Enrollment open: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Nov 7, 2023
P2a, N=15, Recruiting, Sponsor: AltruBio Inc.
Phase classification: P2a --> P2 Not yet recruiting --> Recruiting
- || leiolizumab (ALTB-268) / AltruBio
New P2 trial, New P2a trial: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (clinicaltrials.gov) - Oct 31, 2023
P2a, N=15, Not yet recruiting, Sponsor: AltruBio Inc.
- neihulizumab (ALTB-168) / AltruBio, leiolizumab (ALTB-268) / AltruBio
ALTB-268, a Tetravalent anti-psgl-1 Antibody Derived from ALTB-168, Shows Enhanced Potency in Treating T Cell Mediated Inflammatory Diseases () - Jun 5, 2023 - Abstract #FOCIS2023FOCIS_227;
Most importantly, a similar safety profile as ALTB-168 was observed for ALTB-268 in NHP toxicology assessments, with a NOAEL of 120 mg/kg in a definitive 28-day weekly repeat-dose toxicity study, and a bioavailability of 70% by subcutaneous (sc) route. These data support the clinical development of ALTB-268, sc, for the treatment of T-cell mediated inflammatory diseases.
- ||| leiolizumab (ALTB-268) / AltruBio
New P1 trial: A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers (clinicaltrials.gov) - Feb 13, 2023
P1, N=64, Recruiting, Sponsor: AltruBio Inc.